References

EASL clinical practice guidelines on the management of hepatitis B virus infection

10.1016/j.jhep.2025.03.018 · 2025 · External reference

Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0

10.3350/cmh.2024.0780 · 2025 · External reference

Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation

10.1016/j.jhep.2021.02.017 · 2021 · External reference

Emerging serum biomarkers for chronic hepatitis B: Focus on serum HBV RNA and HBcrAg

10.14218/jcth.2025.00064 · 2025 · External reference

Serum HBsAg and HBcrAg is associated with inflammation in HBeAg-positive chronic hepatitis B patients

10.3389/fcimb.2023.1083912 · 2023 · External reference

HBcrAg identifies patients failing to achieve HBeAg seroconversion treated with pegylated interferon alfa-2b

10.4103/0366-6999.189904 · 2016 · External reference

HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics

10.1016/j.jhep.2016.03.013 · 2016 · External reference

A critique and systematic review of the clinical utility of hepatitis B core-related antigen

10.1016/j.jhep.2022.12.017 · 2023 · External reference

Sensitive enzyme immunoassay for hepatitis B virus. core-related antigens and their correlation to virus load

10.1128/jcm.40.2.439-445.2002 · 2002 · External reference

Hepatitis B core-related antigen: A novel and promising. surrogate biomarker to guide anti-hepatitis B virus therapy

10.3350/cmh.2022.0434 · 2023 · External reference

Hepatitis B virus infection--natural history and clinical consequences

10.1056/nejmra031087 · 2004 · External reference

Overview of hepatitis B viral replication and genetic variability

10.1016/j.jhep.2016.01.027 · 2016 · External reference

Review article: novel biomarkers in hepatitis B infection

10.1111/apt.17105 · 2022 · External reference

Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection

10.1111/apt.14376 · 2018 · External reference

Adaptive immunity in HBV infection

10.1016/j.jhep.2016.01.026 · 2016 · External reference

Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection

10.1136/gutjnl-2021-324646 · 2022 · External reference

Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients

10.1016/j.jhep.2018.11.030 · 2019 · External reference

Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B

10.1038/s41598-017-00111-0 · 2017 · External reference

Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA

10.1111/liv.13346 · 2017 · External reference

Clinical evaluation of hepatitis B core-related antigen in chronic hepatitis B and hepatocellular carcinoma patients

10.1016/j.cca.2018.07.027 · 2018 · External reference

Hepatitis B virus (HBV) core-related antigen during nucleos(t)ide analog therapy is related to intra-hepatic HBV replication and development of hepatocellular carcinoma

10.1093/infdis/jiv572 · 2016 · External reference

Hepatitis B virus DNA integration: In vitro models for investigating viral pathogenesis and persistence

10.3390/v13020180 · 2021 · External reference

Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm

10.3350/cmh.2022.0420 · 2023 · External reference

High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy

10.1111/liv.16029 · 2024 · External reference

End-of-treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT flares in chronic hepatitis B patients

10.1016/j.jmii.2022.06.002 · 2023 · External reference

Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation

10.1093/jac/dkac409 · 2023 · External reference

Quantitative measurement of serum HBcrAg can be used to assess the feasibility of safe discontinuation of antiviral therapy for chronic hepatitis B

10.3390/v16040529 · 2024 · External reference

Hepatitis B core-related antigen is a biomarker for off-treatment relapse after long-term nucleos(t)ide analog therapy in patients with chronic hepatitis B

10.2147/ijgm.s321253 · 2021 · External reference

Association of hepatitis B core-related antigen with hepatitis B virus reactivation in occult viral carriers undergoing high-risk immunosuppressive therapy

10.1038/ajg.2016.436 · 2016 · External reference

Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy

10.1111/j.1872-034x.2007.00094.x · 2007 · External reference

Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk

10.1111/apt.15058 · 2019 · External reference

Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients

10.1007/s00535-015-1153-1 · 2016 · External reference

Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection

10.1016/j.hepres.2006.08.005 · 2006 · External reference

JSH guidelines for the management of hepatitis B virus infection

10.1111/hepr.12269 · 2014 · External reference

Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B

10.1111/liv.13046 · 2016 · External reference

Relationship between hepatitis B core-related antigen levels and sustained HBeAg seroconversion in patients treated with nucleo(s)tide analogues

10.1111/jvh.13097 · 2019 · External reference

Baseline and on-treatment HBcrAg levels as predictors of HBeAg seroconversion in chronic hepatitis B patients treated with antivirals

10.1111/jvh.13765 · 2023 · External reference

Hepatitis B core-related antigen levels predict pegylated interferon-α therapy response in HBeAg-positive chronic hepatitis B

10.3851/imp3367 · 2020 · External reference

Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues

10.1111/apt.15108 · 2019 · External reference

HBcrAg-based risk score performs better than the HBV DNA-based scores for HCC prediction in grey zone patients who are HBeAg-negative

10.1016/j.jhepr.2023.100956 · 2023 · External reference

Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B

10.1002/jmv.28210 · 2023 · External reference

Ultrasensitive assay for hepatitis B core-related antigen predicts hepatocellular carcinoma incidences during entecavir

10.1002/hep4.1819 · 2022 · External reference

Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection

10.1200/jco.2009.27.4456 · 2010 · External reference

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

10.1002/hep.29800 · 2018 · External reference

The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy

10.3350/cmh.2016.0045 · 2016 · External reference

Potential of ultra-highly sensitive immunoassays for hepatitis B surface and core-related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen seroclearance

10.1111/hepr.13602 · 2021 · External reference

Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay

10.1007/s12072-012-9354-7 · 2012 · External reference

A longitudinal study to detect hepatitis B surface and core-related antigens in chronic hepatitis B patients with hepatitis B surface antigen seroclearance using highly sensitive assays

10.1016/j.jcv.2022.105375 · 2023 · External reference

End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB

10.1016/j.jhep.2022.01.021 · 2022 · External reference

Discontinuation of nucleos(t)ide analogues after NA-induced HBsAg seroclearance: a single-center 48-week retrospective study

10.1016/j.jve.2025.100617 · 2025 · External reference

Two concepts of hepatitis B core-related antigen assay: A highly sensitive and rapid assay or an effective tool for widespread screening

10.3390/v16060848 · 2024 · External reference

Analytical validation of hepatitis B core-related antigen (HBcrAg) using dried blood spots (DBS)

10.1111/jvh.13489 · 2021 · External reference

Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load

10.1016/j.jhep.2021.04.051 · 2021 · External reference

Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatment

10.1172/jci161818 · 2022 · External reference

Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA

10.1111/jvh.13061 · 2019 · External reference

Hepatitis B core-related antigen as a promising serological marker for monitoring hepatitis B virus cure

10.4254/wjh.v17.i1.98658 · 2025 · External reference

Utility of novel viral and immune markers in predicting HBV treatment endpoints: A systematic review of treatment discontinuation studies

10.1016/j.jhepr.2023.100720 · 2023 · External reference

Hepatitis B surface antigen, core-related antigen and HBV RNA: Predicting clinical relapse after NA therapy discontinuation

10.1111/liv.14606 · 2020 · External reference

Hepatitis B Virus RNA as a biomarker for safe antiviral discontinuation: A prospective study of nucleos(t)ide analogue withdrawal

10.1093/infdis/jiae541 · 2025 · External reference

Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation

10.1136/gutjnl-2020-321116 · 2021 · External reference

HBeAg-positive patients with HBsAg  < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation

10.1007/s00535-021-01812-0 · 2021 · External reference

HBcrAg values may predict virological and immunological responses to pegIFN-α in NUC-suppressed HBeAg-negative chronic hepatitis B

10.1136/gutjnl-2024-332290 · 2024 · External reference

VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study

10.1016/s2468-1253(24)00237-1 · 2024 · External reference

Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B

10.1016/j.jhep.2024.08.010 · 2025 · External reference

Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D

10.1016/j.cmi.2015.02.010 · 2015 · External reference

Comparison of HBV RNA and hepatitis B core related antigen with conventional HBV markers among untreated adults with chronic hepatitis B in north america

10.1002/hep.32018 · 2021 · External reference

Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis

10.1111/apt.16258 · 2021 · External reference

Evaluation of Hepatitis B core-related antigen (HBcrAg) as a biomarker in cohorts from the United Kingdom and South Africa

10.1016/j.jinf.2025.106601 · 2025 · External reference

Profiles of HBcrAg and pgRNA in pregnant women with chronic HBV under different disease phases and antiviral prophylaxis

10.1093/ofid/ofae241 · 2024 · External reference

PgRNA closely correlates to cytokine profile in HBeAg-positive pregnant women undergoing prophylactic antiviral intervention

10.3389/fimmu.2024.1511855 · 2024 · External reference